Company: TAK
Filing Date: 2025-03-03
Form Type: 6-K
Source: 0001395064-25-000034
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-03-03
Form: 6-K
Chunk 1
---
ycythemia Vera

#### OSAKA, Japan, March 3, 2025 –
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced positive topline results for the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV). Please see the attached press release for details.

| Media Contact:        |     | Investor Contact:              |
| Emy Gruppo            
 emy.gruppo@takeda.com |     | Christopher O’Reilly           
 christopher.oreilly@takeda.com |

The impact on Takeda’s financial results for the fiscal year ending March 31, 2025 (FY2024), following the study results, is immaterial.

<div align='center'>###</div>

New Release

<div align='center'>Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera</div>

− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo

− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes

− Rusfertide was generally well tolerated; no new safety findings were observed in the study

NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025 – Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA).

Key findings from the study include:

• The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those